Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00536367
Other study ID # 2005H0241
Secondary ID
Status Completed
Phase N/A
First received September 25, 2007
Last updated June 11, 2014
Start date January 2006
Est. completion date March 2008

Study information

Verified date June 2014
Source Ohio State University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this protocol is to determine if the 3 variable mortality prediction model established using data from a retrospective, multi-center patient registry (The ADHERE Acute Decompensated HEart FailuRE National Registry) will hold for a prospective, observational outcome study of OSU patients diagnosed in the Emergency Department (ED)with Acute Decompensated Heart Failure (ADHF). In the retrospective registry, three parameters were found to be highly predictive of inpatient mortality for patients admitted with ADHF - on admission, BUN > 43 mg/dL, systolic BP < 115 mmHg, and Cr > 2.75 mg/dL. However, the very nature of the ADHERE database limited the analytic potential of this model, as the data captured by ADHERE is retrospective and limited to the inpatient stay, and the only outcome evaluated was inpatient mortality. Due to its inherent limitations, the model did not and could not address longer term outcomes, such as repeat visits to the emergency department after discharge, or need for readmission to an acute care setting, which frequently occurs soon after discharge in patients who survive to discharge after being admitted with ADHF.

This observational study will create a registry of patient information obtained from an interview with the patient and a review of the patient's medical record. Follow up information at 30 days post discharge will be obtained by phone interview with the patient and a review of the patient's OSUMC visit history.

Most ED patients diagnosed with ADHF are admitted, as emergency physicians are aware that heart failure in general carries a very high mortality rate. However, as risk stratification for ADHF is a severely under researched area, it is not at all clear which patients with acutely decompensated heart failure will have a poor outcome in the short and intermediate term. With an improved understanding of the risk profile of our ADHF patients, more appropriate decision making and disposition assignment can be made.


Description:

Congestive heart failure (CHF) affects nearly 5 million people in the United States and is steadily increasing in prevalence. It is the single most expensive diagnosis for CMS in the United States, responsible for one million hospitalizations per year. There is a wealth of evidence based management strategies for the long term care of the patient with chronic, stable heart failure. Unfortunately, there is a dearth of evidence for the management of the patient with acutely decompensated heart failure. By way of illustration, the American College of Cardiology and the American Heart Association (ACC/AHA) issued a voluminous guideline for the management of chronic CHF; to date no recommendations for the management of ADHF have been issued by the ACC/AHA.

As this is an observational study, the experimental portion is solely data collection. The research team will not attempt to guide clinical care. Demographic data, vital signs at presentation, medical history, advance directive status, laboratory values on admission (BNP, BUN, Cr, troponin), use of intravenous vasoactive medications, laboratory values if discharged alive (discharge BNP, BUN, Cr), critical care utilization, final discharge diagnosis, and hospital length of stay will be collected. Patients will be contacted by phone at 30 days from initial presentation to assess survival, ED usage, and rehospitalization.

Specific Aim #1: We will evaluate the performance of the three factor model (BUN > 43 mg/dL, systolic blood pressure < 115 mmHg, Cr < 2.75 mg/dL) using a prospective cohort of all patients admitted with a primary diagnosis of ADHF to predict ICU utilization and hospital length of stay.

Specific Aim #2: We will test the ability of the model to predict an expanded combined endpoint of mortality, readmission to an Emergency Department, and readmission to an inpatient or observation setting within 30 days of presentation with ADHF.

Specific Aim #3: We will incorporate and test additional variables into the Fonarow model to derive a rule to predict the 30 day combined endpoint of death, readmission to an Emergency Department, and readmission to an inpatient or observation setting within 30 days of presentation with ADHF.


Recruitment information / eligibility

Status Completed
Enrollment 226
Est. completion date March 2008
Est. primary completion date July 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- age 18 or older

- presentation to the Emergency Department and/or admission to the hospital with diagnosis of acute decompensated heart failure

Exclusion Criteria:

- minors

- prisoners

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Other:
No intervention - observational study only


Locations

Country Name City State
United States The Ohio State University Medical Center Columbus Ohio

Sponsors (2)

Lead Sponsor Collaborator
Brian Hiestand MD Emergency Medicine Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 30 day admit rate examination of 30 day recidivism for heart failure admission patients 30 days
See also
  Status Clinical Trial Phase
Completed NCT01357850 - A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure Phase 2
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Completed NCT00531661 - CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients N/A
Terminated NCT00383630 - Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure Phase 2
Terminated NCT00125437 - Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy N/A
Completed NCT00149435 - Cardiovascular Health Study (CHS) Events Follow-up Study
Completed NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment Phase 2
Completed NCT00241761 - Epidemiology of Depression and Heart Failure in Aging N/A
Completed NCT00094263 - Long-Term Predictors of Morbidity in Older Age N/A
Terminated NCT00357591 - Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation N/A
Completed NCT00202579 - Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure Phase 2
Completed NCT00048425 - Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure. Phase 3
Completed NCT00530426 - Heart Failure Registry Phase 4
Completed NCT00023556 - Genetic Architecture of Heart Disease in Rural Brazil N/A
Terminated NCT00190359 - Growth Hormone and Heart Failure N/A
Completed NCT00004562 - Occluded Artery Trial (OAT) Phase 3
Completed NCT00005265 - Natural History of Coronary Heart Disease N/A
Completed NCT02772068 - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a Early Phase 1
Completed NCT02925546 - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets Phase 1
Completed NCT01074307 - A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea Phase 4